Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice

[1]  G. Cutter,et al.  Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials , 2021, European journal of neurology.

[2]  A. Bargiela,et al.  Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression , 2021, Molecular therapy. Nucleic acids.

[3]  C. Zimmer,et al.  Regional variation of thigh muscle fat infiltration in patients with neuromuscular diseases compared to healthy controls. , 2021, Quantitative imaging in medicine and surgery.

[4]  R. Artero,et al.  Myotonic dystrophy type 1 drug development: A pipeline toward the market , 2021, Drug discovery today.

[5]  R. Weiss,et al.  Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program , 2021, Neurology.

[6]  P. Nopoulos,et al.  Quantitative muscle MRI as a sensitive marker of early muscle pathology in myotonic dystrophy type 1 , 2021, Muscle & nerve.

[7]  H. Andersen,et al.  Isokinetic strength and degeneration of lower extremity muscles in patients with myotonic dystrophy; an MRI study , 2020, Neuromuscular Disorders.

[8]  A. Bargiela,et al.  The hallmarks of myotonic dystrophy type 1 muscle dysfunction , 2020, Biological reviews of the Cambridge Philosophical Society.

[9]  G. García-Martí,et al.  The Role of Imaging Biomarkers in the Assessment of Sarcopenia , 2020, Diagnostics.

[10]  Christine Péladeau,et al.  Overexpression of Staufen1 in DM1 mouse skeletal muscle exacerbates dystrophic and atrophic features. , 2020, Human molecular genetics.

[11]  H. Reyngoudt,et al.  The expanding role of MRI in neuromuscular disorders , 2020, Nature Reviews Neurology.

[12]  M. Swanson,et al.  HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy , 2020, Proceedings of the National Academy of Sciences.

[13]  D. Furling,et al.  miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy , 2019, Molecular therapy. Nucleic acids.

[14]  Guillaume Bassez,et al.  Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI , 2019, Neurology.

[15]  G. Della Marca,et al.  Prevalence and predictor factors of respiratory impairment in a large cohort of patients with Myotonic Dystrophy type 1 (DM1): A retrospective, cross sectional study , 2019, Journal of the Neurological Sciences.

[16]  T. Khoo,et al.  Respiratory dysfunction in myotonic dystrophy type 1: A systematic review , 2019, Neuromuscular Disorders.

[17]  M. Nakamori,et al.  Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms. , 2018, ACS chemical biology.

[18]  T. Cooper,et al.  Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1 , 2018, Human molecular genetics.

[19]  Jin-Hong Shin,et al.  Lower limb muscle magnetic resonance imaging in myotonic dystrophy type 1 correlates with the six-minute walk test and CTG repeats , 2018, Neuromuscular Disorders.

[20]  V. Rakocevic-Stojanovic,et al.  Magnetic resonance imaging of leg muscles in patients with myotonic dystrophies , 2017, Journal of Neurology.

[21]  C. Angelini,et al.  Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I , 2017, The Journal of clinical investigation.

[22]  L. Gutmann,et al.  Myotonic Dystrophy Type 1 Management and Therapeutics , 2016, Current Treatment Options in Neurology.

[23]  G. Sergi,et al.  Imaging of sarcopenia. , 2016, European journal of radiology.

[24]  P. Carlier,et al.  Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials , 2016, Journal of neuromuscular diseases.

[25]  I. Illa,et al.  Muscle MRI in muscular dystrophies , 2015, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[26]  G. Carter,et al.  Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. , 2015, Human molecular genetics.

[27]  T. Jensen,et al.  Molecular mechanisms in DM1 — a focus on foci , 2015, Nucleic acids research.

[28]  J. Woodgett,et al.  GSK3β mediates muscle pathology in myotonic dystrophy. , 2012, The Journal of clinical investigation.

[29]  F. Metzger,et al.  Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying >1,000 CTG Repeats from the Human DM1 Locus , 2012, PLoS genetics.

[30]  M. Narici,et al.  Sarcopenia, Dynapenia, and the Impact of Advancing Age on Human Skeletal Muscle Size and Strength; a Quantitative Review , 2012, Front. Physio..

[31]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[32]  C. Angelini,et al.  Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells , 2010, Cell Death and Differentiation.

[33]  Guido Gerig,et al.  User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability , 2006, NeuroImage.

[34]  P. Scifo,et al.  Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1. , 2004, The American journal of clinical nutrition.

[35]  A. Paetau,et al.  Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2 , 2003, Neurology.

[36]  S. Cannon,et al.  Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. , 2002, Molecular cell.

[37]  R. J. White,et al.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. , 2000, Science.

[38]  N. Otsu.  A threshold selection method from gray level histograms , 1979 .